ARCALIS will participate in TIDES USA and deliver a talk and two posters at the event.
We are pleased to announce our participation in TIDES USA, taking place from May 19th (Monday) to 22nd (Thursday), 2025, at Manchester Grand Hyatt San Diego in San Diego, CA, USA. As a key exhibitor, we will also deliver insightful oral and poster presentations. We warmly invite you to visit our booth and join our presentations to explore our latest advancements and innovative solutions in RNA-based technologies.
【Event details】
Official website: TIDES USA: Oligonucleotide and Peptide Therapeutics
【Booth information】
Date: May 20th (Tue) -22nd (Thu), 2025
Venue: Manchester Grand Hyatt San Diego, in San Diego, CA, USA, Booth B-100
Access: Manchester Grand Hyatt San Diego | Book Your Waterfront Hotel Today
【Oral presentation】
Strategies to establish effective and safe mRNA-based therapeutics: Hamid Trimech
【Abstract】
ARCALIS, Inc, is a CDMO to manufacture mRNA-based therapeutics for cancer vaccines, rare diseases and infectious disease, providing our customers with seamless services from mRNA design to large-scale manufacturing. Moreover, in collaboration with our sister company, ADDP, ARCALIS supports our customers from mRNA design to in vivo tests using animal models necessary for IND in 7 months. Our commercial production of self-amplifying mRNA (saRNA) for COVID-19 vaccine, KOSTAIVE, was initiated in 2024 at our drug substance facility. In this presentation, Strategies to develop effective and safe mRNA-based therapeutics will be presented in aspects of nucleotide sequence optimization, minimization of undesirable dsRNA, mRNA-LNP formulation and our commercial manufacturing of saRNA.
【Poster presentation】
Correlation between Quality Attributes and Bioactivities of mRNA-Lipid Nanoparticles:
Dr. Susumu Ito (Poster Number 59)
Strategies to establish effective and safe mRNA-based therapeutics:
Dr. Akiko Yanagiya (Poster Number 36)